Roche Expands Digital Pathology Open Environment with Integration of Advanced AI Algorithms from New Collaborators

These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by employing cutting-edge AI technology.

Roche delivers an end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated AI-based clinical image analysis algorithms. Roche reduces variables that can impact analysis, with this end-to-end development generating quality results healthcare providers and researchers can rely on. Following the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented AI tools into routine clinical practice. The Roche Digital Pathology Open Environment acts as a collaborative platform that integrates innovative AI-based pathology tools.

Roche’s collaborators include:

• Deep Bio: Algorithm for prostate cancer detection, grading, and tumor quantification
• DiaDeep: Algorithms for breast cancer biomarker quantification
• Lunit: Tumor proportion score (TPS) analysis for non-small cell lung cancer
• Mindpeak: Algorithms for breast biomarkers and pan tumor PD-L1 for lung, gastric, esophageal, bladder, and breast cancers
• Owkin: Algorithm for the screening of microsatellite stability in colorectal cancer
• Qritive: Algorithms for screening and grading of prostate cancer, analyzing lymph nodes for metastasis, and screening for colon cancer
• Sonrai Analytics: Algorithm for determining microsatellite instability (MSI) status in colorectal cancer
• Stratipath: Algorithm for risk profiling of invasive breast cancer

The seamless integration is facilitated through Roche's navify® Digital Pathology enterprise software, an application for the pathologist's workflow, which now incorporates a wide range of AI-driven algorithms, offering easy access to third-party innovation. These AI tools are designed to improve pathology insights, aiding benefit cancer patients through precision medicine and enabling targeted treatments. These new collaborations and integrations are in line with Roche’s commitment to improving patient outcomes and advancing personalized healthcare by offering scientists and clinicians the resources required to deliver accurate and reliable cancer diagnoses.

"We are excited to welcome these new collaborators into our digital pathology ecosystem," said Jill German, Head of Pathology Lab for Roche Diagnostics. "By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionize cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide."